

REMARKS

In response to the Notice to Comply, the “Brief Description of the Drawings” section of the specification is amended to insert sequence identifiers for the amino acid sequences shown in Figures 1, 3 and 4. No new matter has been introduced by these amendments. In addition, the Notice to Comply states that the nucleic acid sequence shown on page 17, line 2, appears to be in the 3’ to 5’ direction. However, the recited sequence is properly listed in the 5’ to 3’ direction in the specification and in the sequence listing. Applicants note that the name of nucleic acid sequence “mB7-2-3’ PCR oligo” denotes that it is a reverse primer, and not that it is written in the 3’ to 5’ direction. Thus, Applicants submit the application is in compliance with the requirements of 37 C.F.R. §§1.821-1.825.

Applicants believe the foregoing is fully responsive to the Notice to Comply.
Examination of the application is requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Jodi L. Connolly/
Jodi L. Connolly, Ph.D.
Registration No. 54,044